Novartis Reports Results of Zolgensma in P-III STR1VE-EU Study for SMA Type 1

 Novartis Reports Results of Zolgensma in P-III STR1VE-EU Study for SMA Type 1

Novartis Reports Results of Zolgensma in P-III STR1VE-EU Study for SMA Type 1

Shots:  

  • The P-III STR1VE-EU study involves assessing Zolgensma (IV) in patients with SMA Type 1 aged <6mos. at the time of gene therapy, with 1 or 2 copies of the SMN2 backup gene and have bi-allelic SMN1 gene deletion or point mutations
  • Results: 65.6% achieved motor milestones not observed in the natural history of SMA Type 1, 66.7% were free of feeding support, 93.9% are able to swallow thin liquids, 30.3% required feeding support, 27.3% required ventilatory support; 97% patients in ITT population survived event-free, including 93.8% & 56.3% who could have reached 10.5mos. & 13.6 mos. of age respectively
  • New interim P-III STR1VE-EU data presented at WMS support the clinical evidence demonstrating a consistent, transformative benefit across Zolgensma clinical trials for the treatment of patients with SMA

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Mint

Related News: Novartis’ Zolgensma (onasemnogene abeparvovec) Receives MHLW’s Approval for Spinal Muscular Atrophy

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post